JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
Vous n'êtes pas connecté
We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.
JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.
Investors interested in LMT should refrain from buying the stock right now, considering its premium valuation. However, its upbeat estimates and...
At least 62 members of 118th Congress have violated a federal insider trading and conflicts-of-interest law, a Raw Story analysis of congressional...
One should refrain from buying FSLR right now considering its premium valuation. Yet, those who own it may continue to do so considering its upbeat...
BA's long-term prospects remain bright. However, for now, one should refrain from buying this stock, considering its poor year-to-date performance,...
FTNT's ability to monetize its educational initiatives and cutting-edge cybersecurity solutions make the stock worth buying despite fierce...
FTNT's ability to monetize its educational initiatives and cutting-edge cybersecurity solutions make the stock worth buying despite fierce...
What is the MENA region? MENA is the acronym for “Middle East and North Africa”, regularly used in academic and business writings. It refers...
Pharmacies can now stock therapeutic vapes – but many are holding back on ethical grounds or believe registration for the new system is too onerous.